Back

Novel insights into the management of German patients with very high cardiovascular risk eligible for PCSK9 inhibitor treatment: baseline characteristics from the PERI-DYS study

27 August 2021 (08:00 - 20:00)
Organised by:
Congress Presentation Part of: Risk Factors and Prevention ePosters Lipids ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Professor Ulrich Laufs

University Hospital Leipzig, Leipzig (Germany)

224 More presentations in this session

Presentation thumbnail
High risk characteristics in patients with hypertrophic cardiomiyopathy for predicting cardiovascular events
Doctor B. Keskin Meric (London, GB)
Abstract Slides
Presentation thumbnail
Cardiac biomarkers as prognosticators among SARS-CoV-19 patients in a tertiary hospital in Philippines
Doctor R. Ong (Makati, PH)
Abstract Slides
Presentation thumbnail
Prevalence of atherosclerosis risk factors in Egyptian patients with acute coronary syndromes; final data of the nationwide cross-sectional CardioRisk project
Doctor A. Bendary (Benha, EG)
Abstract Slides
Presentation thumbnail
SF-12 Physical and Mental Health Scales predict cardiovascular events after hospitalization
Mr R. Gascuena (Leganes, ES)
Abstract Slides
Presentation thumbnail
Comparison of traditional versus artificial intelligence based coronary artery disease risk prediction scores in young patients with acute coronary syndrome
Doctor S. Vohra (Lucknow, IN)
Abstract Slides

Access the full session

Session thumbnail
Risk Factors and Prevention ePosters

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August 2021 08:00 CET
You may be interested in
thumbnail
Congress Presentation
PCSK9 inhibitors and cardiovascular outcomes in AMI-BIRISK patients: a multicenter retrospective study
1 September 2025
thumbnail
Congress Presentation
Prevalence and clinical relevance of familial hypercholesterolemia-causing mutations in Germany
4 April 2025
thumbnail
Congress Presentation
High long-term persistence to evolocumab treatment regimens in European clinical practice: analysis of the HEYMANS registry
27 August 2022
thumbnail
Congress Presentation
The differences in lipid lowering therapies and the LDL-C goal attainment in patients with ASCVD documented by cardiologists and general practitioners in Germany.
30 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources